All News
Not Still’s – Now What?
Your patient doesn't meet criteria for Still’s disease (AOSD or sJIA), now what should you do or consider?
What you do or consider next can be addressed according to the stage of current disease: A) Hospitalized Febrile Disease, or B) Outpatient “Still’s” Disease.
Social Media Questions (7.29.2022)
Dr. Jack Cush reviews the news, journal reports and rheumatologist cases from the past week on RheumNow.com. This podcast is brought to you by StillsNow.com - be sure to sign up for our monthly StillsNow email and Monthly StillsNow Podcast.
Read Article
Belimumab (Benlysta) has been FDA approved for use in pediatric patients with active lupus nephritis who are receiving standard lupus therapy. The approval in kids is for the IV formulation only; SC belimumab is for SLE and LN in adults https://t.co/TKyNDwIUQH https://t.co/6VaMOMfwYi
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of cardiovascular effects of Colchicine: 21 RCTs (15,569 pts shows colchicine was superior to placebo reducing CV events; with lower risk recurrent pericarditis (RR 0.50), MACE (RR 0.67), & AFib recurrence (RR 0.68) https://t.co/hksDaCSj02 https://t.co/eGRVqZiBBx
Links:
Dr. John Cush RheumNow ( View Tweet)
Nintedinib’s Durable Efficacy in Systemic Sclerosis
Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said.
https://t.co/5M92Yhpeo1 https://t.co/qZvwfLs1jx
Links:
Dr. John Cush RheumNow ( View Tweet)
EMA in Europe has approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who are DMARD-IR or biologic-IR. Based on 3 phase III trials. https://t.co/CbRQGzxJEr https://t.co/SlJNprUay3
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast—Dr.Cush answers your questions!
https://t.co/cif6yo0tGi https://t.co/kia5J0OMf6
Links:
Dr. John Cush RheumNow ( View Tweet)
Japanese SLE registry looked at infection risk with Prednisolone (PSL). Among 509 SLE pts (47 yrs); 77% used immunosuppressants & 52 had hospitalized infxns. Signif higher SIE w/ PSL 5.0–7.5 mg (aHR 6.8) & PSL 7.6-15 mg (aHR 7.6) vs 0-2.5 mg/d https://t.co/xZ5Yx4X1uw https://t.co/FSfsTENeUx
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 245 active SLE pts followed x 2 yrs shows low disease activity (LLDAS) achieved in 63%. By multivariate analysis, negative predictors of LLDAS were nephritis, heme involvement & low C3/C4. Early LLDAS predicted future LLDAS-50 https://t.co/IQaDFRtrZy https://t.co/G6MdBOMftX
Links:
Dr. John Cush RheumNow ( View Tweet)
TNR: Still's Now Journal Club - Pivotal Trials in SJIA & AOSD Approved Meds
This week's Stills disease Journal Club features expert panelists Drs. Olga Petryna, Daniel Lovell, Hermine Brunner and Jack Cush.
https://t.co/2TCtByJg4Q https://t.co/arqQUQJNNC
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatic Causes for Fever of Unknown Origin
Fever of unknown origin (FUO) represents a diagnostic challenge to many physicians and while cancer and infectious causes need to be excluded, rheumatic disorders are amongst the most common causes of FUO.
https://t.co/JXcp2k6hJ1 https://t.co/5i97sKde8n
Links:
Dr. John Cush RheumNow ( View Tweet)
I had the chance to discuss intrinsic protection from Covid with my friend @ASlavitt
https://t.co/dI993XBoXr https://t.co/lidQnzgjJg
Links:
Eric Topol EricTopol ( View Tweet)
Have the trends started to change in awards for more junior people in rheumatology? https://t.co/0UC9BvXfsY
Rheum Cat rheum_cat ( View Tweet)
15 Powerful Visuals About Psychology & Life
1. https://t.co/ZY6QwhA9bK
Philosophy Pathfinder PhilosophyPath ( View Tweet)
Our commentary on the SELECT-AXIS 2 trial is also available: https://t.co/dkB2h6OeKJ
@Spondy_MD https://t.co/GIDXVnhHcz
Rheum Cat rheum_cat ( View Tweet)
Get insights to difficult to treat rheumatoid arthritis #D2T from the experts👉 This report summarizes what we know and what we still need to know! https://t.co/Qdkcu0Z2sk https://t.co/FW5rvSK1vi
ARD & RMD Open ARD_BMJ ( View Tweet)
Best Labs for Still’s Disease
There is no “test” (blood or other) that is solely diagnostic of Still’s disease, but labs can help make a diagnosis or manage disease, and affirm the safety of drugs in use.
What tests should you be ordering?
https://t.co/24QSfEEVwG https://t.co/bdrvSBd652
Links:
Dr. John Cush RheumNow ( View Tweet)
The Johns Hopkins Hospital has repeated its top rank among US Rheumatology centers - ranking #1 for the 18th year in a row, according to U.S. News & World Report’s 2022–23 Best Hospitals list.
https://t.co/dC5vVEhCrC https://t.co/skXbg1fAve
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 63 Thalassemia pts (50 transfusion dep) w/ 22% α-, 73% β-, 5% α- & β-thal. 23 had inflammatory rheumatic Dz (IRD: RA 9, gout 6, SLE 3, SpA 2). ANA+ in 10% w/o IRD & Transfusion Dep had more + tests for direct Coombs & ANA https://t.co/QW6ecv98F1 https://t.co/GO3xC86hLc
Links:
Dr. John Cush RheumNow ( View Tweet)
TREAT EARLIER Study - Is MTX Intevention in Pre-Clinical RA Warranted?
https://t.co/rGcm1DSwJk https://t.co/paBrJVMXdP
Links:
Dr. John Cush RheumNow ( View Tweet)